FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study

Colon Cancer Clinical Trial

— FORCE  

Official title:

FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03291951
• Other study ID #: CN-17-2877
• Status: Completed
• Phase: N/A
• Start date: February 23, 2018
• Est. completion date: March 21, 2022

Study information

• Verified date: July 2022
• Source: Kaiser Permanente
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

FORCE is a randomized home-based resistance training/strength training (RT) intervention study for Stage II and III colon cancer patients undergoing chemotherapy.

Participants will be 180 newly diagnosed Stage II and III colon cancer patients from Kaiser Permanente of Northern California (KPNC), the Penn State Cancer Institute (PSCI), and the Dana Farber Cancer Institute (DFCI). The intervention will begin within the first weeks of adjuvant chemotherapy and continue exercise through the completion of post-operative chemotherapy. Specifically, the investigators will examine between group differences for RT versus waitlist control for chemotherapy outcomes including dose delays, dose reductions, early stoppage and Grade 3 and 4 toxicities. The investigators will also study changes in muscle mass (MM) and changes in specific inflammatory markers (e.g. CRP, IL-6 and TNF-RII) as potential markers of change in response to RT. To determine effects of change of MM on chemotherapy-specific drug clearance, the investigators will examine the impact body composition changes on the pharmacokinetics (PK) of 5-FU and oxaliplatin, two of the most commonly used drugs for colon cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 183
• Est. completion date: March 21, 2022
• Est. primary completion date: March 21, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men and women =18 years

• Newly diagnosed with histologically confirmed stage II-Ill colon cancer

• Completed curative-intent surgical resection

• Currently prescribed one of the following adjuvant chemotherapy regimens: (IV 5-fluorouracil [5-FU] / leucovorin [LV], capecitabine, FOLFOX [5-FU, LV, oxaliplatin], CAPOX [capecitabine and oxaliplatin]

• Patients must have started chemotherapy or plan to start with receipt of the first exercise visit by 3rd infusion visit. Patients enrolled at the Dana-Farber Cancer Institute and who are receiving FOLFOX chemotherapy are eligible to enroll in the pharmacokinetics sub-study.

• No planned major surgery anticipated in the intervention period

• Sufficient time to heal from any major surgery to start of intervention, including colostomy reversal (port-a-cath removal excluded)

• Approval by either oncologist or surgeon to participate in trial

• Readiness as determined by the Physical Activity Readiness Questionnaire

• Ability to understand and the willingness to sign a written informed consent document in English

• Willingness to be randomized

Exclusion Criteria:

• Concurrent actively treated other cancer (except non-melanoma skin cancer, in situ cervical cancer or localized prostate cancer treated with surveillance only)

• Patients with untreated hypertension (>180 mm Hg systolic or >100 mm Hg diastolic) appearing in the patient's medical record in the two weeks prior to screening

• Presence of metastatic disease

• Current strength training >2x week for the past 3 or more months

• Patients enrolled in other clinical trials of weight loss, physical activity or dietary interventions are ineligible.

Related Conditions & MeSH terms

• Chemotherapy Effect
• Colon Cancer
• Colonic Neoplasms
• Resistance Training

Intervention

Behavioral:
• Resistance training
The intervention goal is for study participants to exercise with progressively higher weights for resistance training to achieve a 1-kg increase in lean body mass by the end of the intervention. During an in-person visit on the same day as a chemotherapy infusion session, exercise professionals will teach participants a series of exercises to be completed at home twice weekly throughout the intervention. Participants will also receive protein powder, which they will be instructed to consume with meals twice a day. During subsequent infusion sessions, the exercise professional will meet in-person with participants to evaluate their ability to increase weights, and adjust exercises appropriately. In between visits, the exercise professional will check-in with participants by phone.

Locations

Country	Name	City	State
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Penn State Cancer Institute	Hershey	Pennsylvania
United States	Kaiser Permanente Division of Research	Oakland	California

Sponsors (3)

Lead Sponsor	Collaborator
Kaiser Permanente	Dana-Farber Cancer Institute, Penn State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relative dose intensity (RDI)	Chemotherapy completion rates will be assessed as relative dose intensity for each agent and then average relative dose intensity (ARDI), which considers all chemotherapy agents in a regimen. We will examine differences in RDI for each chemotherapy agent and the ARDI across all agents between the RT group and the UC group.	3-6 months
Primary	Number of moderate and severe chemotherapy-associated toxicities	Moderate and severe chemotherapy-associated toxicities will be assessed via a NCI PRO-CTCAE questionnaire, which is a patient-reported outcome measure developed to evaluate symptomatic toxicity in patients on cancer clinical trials.	3-6 months